# US 2019/0167568 A1 · Transdermal Drug Delivery System and Method for Using Same

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0167568 A1
- Document ID: US20190167568A1
- Status: Published application
- Kind: A1
- Application number: 16/313,739
- Filed: 2017-06-29
- Published: 2019-06-06
- Earliest claimed: 2016-06-29
- Assignees: Senju USA, Inc.; Nichiban Co., Ltd.
- Applicants: Senju USA, Inc.; Nichiban Co., Ltd.
- Inventors: Takahiro OGAWA; Akiharu ISOWAKI; Tetsuo KIDA; Koji KAWAHARA; Emiko TESHIMA; Teppei OSAKO
- Web page: https://patentgrep.com/patent/US20190167568A1

## CPC

- A61K 9/0014: {Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00)}
- A61K 9/7061: {Polyacrylates}
- A61K 31/573: substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
- A61M 37/00: Other apparatus for introducing media into the body (for reproduction or fertilisation A61B17/425; apparatus for iontophoresis or cataphoresis A61N1/30); Percutany, i.e. introducing medicines into the body by diffusion through the skin (salt baths A61H33/04)
- A61P 27/02: Ophthalmic agents
- A61F 9/0008: {Introducing ophthalmic products into the ocular cavity or retaining products therein (putting in contact lenses A61F9/0061; introducing or retaining media in cavities of the body in general A61M31/00)}
- A61K 9/0048: {Eye, e.g. artificial tears}
- A61K 9/7069: {obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide}
- A61K 31/58: containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin (digitoxin {A61K31/7048})
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61M: DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY (introducing media into or onto the bodies of animals A61D7/00; means for inserting tampons A61F13/26; devices for administering food or medicines orally A61J; containers for collecting, storing or administering blood or medical fluids A61J1/05); DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY (surgery A61B; chemical aspects of surgical articles A61L); DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR {(Electrotherapy, e.g. producing anaesthesia by the use of alternating or intermittent currents A61N1/36021)}
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61F: FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS (dental prosthetics A61C)

## Abstract

[PROBLEMS TO BE SOLVED] To provide a method of advantageously improving a transdermal permeation amount of a steroid drug to diseased portions when treating ophthalmic diseases such as chalazion, blepharitis, allergic conjunctivitis, vernal keratoconjunctivitis, and meibomian gland dysfunction. [SOLUTION] To provide the transdermal drug delivery system for administering a drug via the eyelid skins that have been treated with a microneedle array, featured in that the drug is a water-soluble steroid, and the transdermal drug delivery system is a water-containing base adhesive skin patch.

## Claims

### Claim 1

A transdermal drug delivery system for administering a drug for treating ophthalmic diseases via an eyelid skin that has been treated by a microneedle array, wherein
the drug is a water-soluble steroid, and
the transdermal drug delivery system is a water-containing base adhesive skin patch.

### Claim 2 (depends on 1)

The transdermal drug delivery system accordingly to claim 1, wherein
the transdermal drug delivery system is a water-containing adhesive skin patch comprising either adhesive hydrogel, or non-adhesive hydrogel and an adhesive tape for fixation, and
the hydrogel contains a water-soluble steroid as the drug.

### Claim 3 (depends on 1)

The transdermal drug delivery system according to claim 1, wherein
the transdermal drug delivery system is a water-containing base adhesive skin patch obtained by which a water-containing base adhesive layer is arranged on a backing film, and
the water-containing base adhesive layer contains a water-soluble steroid as the drug.

### Claim 4 (depends on 1)

The transdermal drug delivery system according to claim 1, wherein the drug is at least one of the water-soluble steroids selectable from a range of −5 to 0 in octanol/water distribution coefficient (log D).

### Claim 5 (depends on 4)

The transdermal drug delivery system according to claim 4, wherein
the drug is at least one of the water-soluble steroids selectable from the group consisting of dexamethasone sodium phosphate, dexamethasone metasulfobenzoate sodium, hydrocortisone sodium phosphate, hydrocortisone sodium succinate, prednisolone sodium phosphate, prednisolone sodium succinate, methylprednisolone sodium succinate, and betamethasone sodium phosphate.

### Claim 6 (depends on 2)

The transdermal drug delivery system according to claim 2, wherein the water-containing base adhesive layer or hydrogel contains polyvinyl alcohol.

### Claim 7 (depends on 2)

The transdermal drug delivery system according to claim 2, wherein the water-containing base adhesive layer or hydrogel contains at least one kind selectable from the group consisting of polyacrylic acid and salt thereof.

### Claim 8 (depends on 1)

The transdermal drug delivery system according to claim 1, wherein the ophthalmic disease is at least one disease selectable from the group consisting of chalazion, blepharitis, allergic conjunctivitis, vernal keratoconjunctivitis and meibomian gland dysfunction.

### Claim 9 (depends on 1)

A method for treating ophthalmic diseases, the method comprising:
a process of perforating a microneedle on an eyelid skin surface by using a microneedle array; and
a process of locally applying a transdermal drug delivery system according to claim 1 to a portion of an eyelid skin on which perforation of the microneedle has been performed.

### Claim 10 (depends on 1)

A set for treating ophthalmic diseases, wherein the set includes a microneedle array for perforating an eyelid skin, a support base for eyelid skin, and a transdermal drug delivery system according to claim 1.

### Claim 11 (depends on 10)

The set of treating ophthalmic diseases according to claim 10, wherein the support base for eyelid skin is either entropion forceps or a cornea protection plate (lid plate).

### Claim 12

A transdermal drug delivery system for administering a drug for treating ophthalmic diseases via an eyelid skin that has been treated by a microneedle array, wherein
when the drug is a liposoluble steroid, the transdermal drug delivery system further comprises a water-soluble additive, the additive being produced by making the liposoluble steroid esterified to become water soluble, and
the transdermal drug delivery system is a water-containing base adhesive skin patch.

### Claim 13 (depends on 3)

The transdermal drug delivery system according to claim 3, wherein the water-containing base adhesive layer or hydrogel contains polyvinyl alcohol.

### Claim 14 (depends on 3)

The transdermal drug delivery system according to claim 3, wherein the water-containing base adhesive layer or hydrogel contains at least one kind selectable from the group consisting of polyacrylic acid and salt thereof.
